Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Source : https://ar.iiarjournals.org/content/42/5/2783.long
Background/Aim: To evaluate the impact of prophylactic administration of pegfilgrastim in esophageal cancer (EC) patients treated with chemotherapy consisted of docetaxel, cisplatin, and fluorouracil (DCF). Patients and Methods: Among 102...
Conclusion: Prophylactic pegfilgrastim in DCF may relieve adverse events and improve the oncologic outcome of EC patients.
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial - British Journal of Cancer
Source : https://www.nature.com/articles/s41416-022-01846-y
Dose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation.
Conclusions: Overall, no significant differences in survival were found amongst the studied regimens after a long-term observational period.
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35610260/
Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the...
Conclusion: AIS-low patients had poor outcomes, despite receiving adjuvant trastuzumab. However, these patients appear to benefit from an addition of lapatinib. Further studies are needed to validate the significance of this signature to identify patients who are more likely to benefit from dual anti-HER2 therapy.
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35587323/
doi: 10.1007/s10549-021-06469-0. Online ahead of print. 1 Mayo Clinic, Jacksonville, FL, USA. [email protected]. 2 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Daiichi Sankyo, Basking Ridge, NJ, USA....
Conclusion: Differing AE profiles for anti-HER2 therapies should be considered when assessing benefit-risk profile for treatment options.
Pegfilgrastim
Source : https://www.ncbi.nlm.nih.gov/books/NBK532893/
Pegfilgrastim is a pegylated granulocyte colony-stimulating factor that is FDA-approved to decrease the risk of patients developing febrile neutropenia when receiving myelosuppressive chemotherapy regimens. For primary prophylaxis, the risk of...
Relevance: Pegfilgrastim is a pegylated granulocyte colony-stimulating factor that is FDA-approved to decrease the risk of patients developing febrile neutropenia when receiving myelosuppressive chemotherapy regimens. For primary prophylaxis, the risk of developing febrile neutropenia should be 20% or higher, and there should be no other safer...